Adipose Stem Cell Biomarker Detection for Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adipose-derived stem cells cultured in conventional basal media require extensive time for proliferation, limiting their clinical effectiveness, and there is a need for objective analysis of molecular biological features related to their superior clinical effects when cultured in media containing EGF or bFGF.
Innovation Solution
A method for detecting the immunosuppression or proliferation potential of adipose-derived stem cells by measuring the mRNA or protein levels of specific genes (AGPAT9, ANXA10, IGF2BP3, PTGER2, ITGA11, PAWR, and SFRP2) cultured in media with EGF or bFGF, which shows expression differences compared to basal media cultures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adipose-derived stem cells are cultured in a standard basal medium, then the culturing method is simple and conventional, but the cell proliferation is slow and requires a lot of time, making it difficult to obtain clinically effective numbers of cells
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by adding specific growth factors (EGF at 5-20 ng/mL and/or bFGF at 5-20 ng/mL) to the basal medium. This parameter modification transforms the medium from a standard basal medium into a growth-promoting medium that significantly accelerates adipose-derived stem cell proliferation while maintaining cell characteristics, thereby resolving the contradiction between simple culturing and slow proliferation.
2Reliability
If adipose-derived stem cells are cultured in a growth medium containing EGF or bFGF, then the proliferation potential and therapeutic effects are superior, but there is a lack of objective molecular biological markers to analyze and quality control the cultured cells
Solution Approach 1:
The patent replaces subjective clinical effect evaluation with objective molecular biological marker detection. By identifying specific genes (AGPAT9, ANXA10, IGF2BP3, PTGER2, ITGA11, PAWR, SFRP2) whose expression levels differ between cells cultured in basal medium versus growth medium, the invention enables objective measurement and quality control of cell therapeutic agents, thus resolving the contradiction between superior therapeutic effects and lack of detection methods.
3Productivity
If adipose-derived stem cells are cultured in a growth medium containing EGF or bFGF, then the proliferation potential increases and clinical effectiveness improves, but the complexity of the culturing method and medium composition increases
Solution Approach 1:
The patent modifies the culture medium by adding specific growth factors (EGF and/or bFGF) at defined concentrations (5-20 ng/mL each) to the basal medium. This controlled parameter change achieves significant cell proliferation enhancement while maintaining reasonable medium complexity through standardized addition protocols, resolving the contradiction between increased productivity and medium complexity.
Data Source
Figure 1~2
Figure 3
Figure 4A
AI summary
The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.